MIRM - Mirum Pharmaceuticals, Inc.

87.8
-2.290   -2.608%

Share volume: 610,813
Last Updated: 03-03-2026
Pharmaceutical Products/Pharmaceutical Preparations: 3.15%

PREVIOUS CLOSE
CHG
CHG%
$90.09
-2.29
-0.03%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
21%
Profitability 25%
Dept financing 3%
Liquidity 50%
Performance 15%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-4.87%
1 Month
-15.54%
3 Months
22.75%
6 Months
18.36%
1 Year
94.16%
2 Year
206.14%
Key data
Stock price
$87.80
P/E Ratio 
0.00
DAY RANGE
$87.60 - $91.16
EPS 
-$0.47
52 WEEK RANGE
$36.88 - $109.28
52 WEEK CHANGE
$96.68
MARKET CAP 
4.060 B
YIELD 
N/A
SHARES OUTSTANDING 
60.342 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
08-06-2025
BETA 
0.55
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$878,327
AVERAGE 30 VOLUME 
$722,642
Company detail
CEO: Christopher Peetz
Region: US
Website: mirumpharma.com
Employees: 140
IPO year: 2019
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Mirum Pharmaceuticals, Inc. focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. The company's lead product candidate is LIVMARLI, an investigational oral drug for the treatment of progressive familial intrahepatic cholestasis disease.

Recent news